# NRG Oncology: Phase 3 study closed enrollment, 475 enrolled (Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | NRG Oncology |
| Sponsor type | Academic and hospital |
| Study | Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer |
| NCT ID | NCT05050162 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Advanced Head and Neck Squamous Cell Carcinoma; Advanced Hypopharyngeal Squamous Cell Carcinoma; Advanced Laryngeal Squamous Cell Carcinoma; Advanced Oropharyngeal Squamous Cell Carcinoma; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 |
| Intervention types | drug, procedure, other, radiation |
| Target enrollment | 475 |
| Site countries | United States, Canada, Hong Kong, Ireland, Switzerland |
| Posted | 2021-09-20 |
| Planned start | 2022-02-01 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-23 |
| Last update posted | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 475 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05050162). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.